Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccine in Lymphoma and Myeloma
NCT00937183Phase 2Completed
- Start
- Sep 2003
- Primary completion
- Jun 2017
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of autologous dendritic cell vaccine in indolent B-cell lymphoma, multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL). Started Sep 2003; status: completed.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
indolent B-cell lymphomamultiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00937183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00937183.